Common use of HLA Programs Clause in Contracts

HLA Programs. Each Target Program under Section 5.1 above shall be specific to a designated HLA allele. GSK also has the right to nominate further HLA alleles per Nominated Target (each, a “Nominated HLA”) up to a maximum of a total of ten (10) and to be the subject of further Collaboration Programs as set forth in this Section 5.2 (each Collaboration Program directed to a Nominated HLA, an “HLA Program”). GSK may not exercise its right to nominate a Nominated HLA associated with a Nominated Target until such time as GSK has (i) *** ; or (ii) *** in which case GSK shall be entitled to nominate HLA alleles for HLA Programs, to be capped at a number that is twice the number of Nominated Targets at such time (up to a maximum of a total of 15 Target ***Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission. Programs). Following *** by GSK, GSK shall be entitled to nominate any remaining entitlement to HLA Programs.